Dixon B. Kaufman

TL;DR: The CITR shows improvement in primary efficacy and safety outcomes of islet transplantation in recipients who received transplants in 2007–2010 compared with those in 1999–2006, with fewer islet infusions and adverse events per recipient.

TL;DR: These general guidelines will be of assistance to standardize the assessment of islet isolations, making it possible to better interpret and compare procedures from different centers.

TL;DR: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs and should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.

TL;DR: By the first year after transplantation, biopsy-confirmed acute rejection was less frequent with alemtuzumab than with conventional therapy, but among high-risk patients, no significant difference was seen between alemTuzumAB and rabbit antithymocyte globulin, and among high/low immunologic risk patients, the apparent superiority of alem Tuzumabs was restricted to patients at low risk for transplant rejection.

TL;DR: Current understandings and uncertainties in islet–ECM interactions are reviewed and their potential impact on posttransplant engraftment is explained; topics covered include matrix and receptor compositions in native islets, effects of isolation and culture on islet- ECM interactions, and potential for postisolation restoration of islets–ECm interactions.